Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2013 2
2014 1
2021 2
2022 1
2023 2

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Biomarkers for diagnosis and monitoring of celiac disease.
Vives-Pi M, Takasawa S, Pujol-Autonell I, Planas R, Cabre E, Ojanguren I, Montraveta M, Santos AL, Ruiz-Ortiz E. Vives-Pi M, et al. Among authors: montraveta m. J Clin Gastroenterol. 2013 Apr;47(4):308-13. doi: 10.1097/MCG.0b013e31827874e3. J Clin Gastroenterol. 2013. PMID: 23388848 Review.
Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children.
Zapata-Cobo P, Salvador-Martín S, Velasco M, Palomino LM, Clemente S, Segarra O, Moreno-Álvarez A, Fernández-Lorenzo A, Pérez-Moneo B, Montraveta M, Sánchez C, Tolín M, Loverdos I, Fobelo MJ, Navas-López VM, Magallares L, García-Romero R, Sánchez-Hernández JG, Rodríguez A, Bossacoma F, Balboa MJ, Salcedo E, Sanjurjo-Sáez M, López-Fernández LA. Zapata-Cobo P, et al. Among authors: montraveta m. Pharmacol Res. 2023 Aug;194:106859. doi: 10.1016/j.phrs.2023.106859. Epub 2023 Jul 19. Pharmacol Res. 2023. PMID: 37473877 Free article.
Correction to: Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicenter Spanish study.
Garcia-Romero R, de Zabarte Fernandez JMM, Pujol-Muncunill G, Donat-Aliaga E, Segarra-Cantón O, Irastorza-Terradillos I, Medina-Benitez E, Ruiz-Hernández CJ, Carrillo-Palau M, Ros-Arnal I, Rodriguez-Martínez A, Escartin-Madurga L, Gutiérrez-Junquera C, Vicente-Santamaría S, Rodriguez-Belvis MV, Fernández-Fernández S, Alberto-Alonso JR, Montraveta M, Torres-Peral R, Navalon-Rubio M, Navas-López VM, de Carpi JM. Garcia-Romero R, et al. Among authors: montraveta m. Eur J Pediatr. 2021 Sep;180(9):3039-3040. doi: 10.1007/s00431-021-04117-9. Eur J Pediatr. 2021. PMID: 34027626 No abstract available.
Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study.
Garcia-Romero R, Martinez de Zabarte Fernandez JM, Pujol-Muncunill G, Donat-Aliaga E, Segarra-Cantón O, Irastorza-Terradillos I, Medina-Benitez E, Ruiz-Hernández CJ, Carrillo-Palau M, Ros-Arnal I, Rodriguez-Martínez A, Escartin-Madurga L, Gutiérrez-Junquera C, Vicente-Santamaría S, Velasco Rodriguez-Belvis M, Fernández-Fernández S, Alberto-Alonso JR, Montraveta M, Torres-Peral R, Navalon-Rubio M, Navas-López VM, Martin de Carpi J. Garcia-Romero R, et al. Among authors: montraveta m. Eur J Pediatr. 2021 Sep;180(9):3029-3038. doi: 10.1007/s00431-021-04063-6. Epub 2021 Apr 20. Eur J Pediatr. 2021. PMID: 33880650
Comments on: Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children.
Zapata-Cobo P, Salvador-Matín S, Velasco M, Palomino LM, Clemente S, Segarra O, Moreno-Álvarez A, Fernández-Lorenzo A, Pérez-Moneo B, Montraveta M, Sánchez C, Tolín M, Loverdos I, Fobelo MJ, Navas-López VM, Magallares L, García-Romero R, Sánchez-Hernández JG, Rodríguez A, Bossacoma F, Balboa MJ, Salcedo E, Sanjurjo-Sáez M, López-Fernández LA. Zapata-Cobo P, et al. Among authors: montraveta m. Pharmacol Res. 2023 Sep 23:106938. doi: 10.1016/j.phrs.2023.106938. Online ahead of print. Pharmacol Res. 2023. PMID: 37748560 No abstract available.